Measuring New Heart Muscle Cells in Infants With Heart Disease
Uses a labeled substance to measure new heart muscle cells in infants with heart disease.
Plain-language title generated from the registry record
Registry title: Quantifying New Heart Muscle Cells
Key facts
- Where
- New York, Philadelphia, and Pittsburgh, United StatesSee the 4 sites
Where in United States
- Columbia University (Morgan Stanley Children's Hospital)New York, United StatesNot yet recruiting
- Weill Cornell MedicineNew York, United StatesTaking people
- Children's Hospital of PhiladelphiaPhiladelphia, United StatesNot yet recruiting
- UPMC Children's Hospital of PittsburghPittsburgh, United StatesNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Weill Medical College of Cornell University
- Trial code
- NCT06587165
- Record updated
- 15 June 2026
- Original description
Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration.Read full original descriptionShow less
A Pilot Study for Quantifying New Heart Muscle Cells
Regenerative therapies could provide new ways of treating heart failure. Unlike many organs in the human body, such as the skin and the GI tract, the ability to regenerate heart muscle decreases after birth, but the precise timing of this decrease and how this decrease is altered in heart disease are uncertain. The investigators will use an innovative approach to quantify cellular heart regeneration in pediatric patients, an appropriate population for determining this decline as well as the potential for reactivating heart muscle regeneration.
The study has now been registered on ClinicalTrials.gov, despite its initiation on July 23, 2015, as registration was not mandated at the original study site, the University of Pittsburgh Medical Center. However, following the transfer of the study to Weill Cornell Medicine, adherence to institutional requirements necessitated its registration on ClinicalTrials.gov.
Inclusion: Patients at 30 days of age to 1 year of age undergoing scheduled elective cardiac surgery will be eligible for study inclusion; The investigators will recruit patients at 30 days of age to 1 year of age with those types of heart disease whose surgical approach has a high probability of myocardial resection; Diagnosis of ToF/PS or other types of heart disease that have a high likelihood of requiring surgery that involves routine resection of myocardium that becomes available for research.
Exclusion: Patients with low chance of having resection of myocardium as part of their surgical care.